Revelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 12,792 shares, an increase of 93.7% from the October 15th total of 6,605 shares. Currently, 2.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 39,572 shares, the short-interest ratio is currently 0.3 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, November 10th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Revelation Biosciences Price Performance
Shares of Revelation Biosciences stock traded down $0.47 on Monday, hitting $3.79. The company had a trading volume of 3,236 shares, compared to its average volume of 33,208. Revelation Biosciences has a twelve month low of $3.08 and a twelve month high of $40.60. The stock has a 50-day moving average of $5.16 and a 200-day moving average of $7.42. The firm has a market capitalization of $2.59 million, a P/E ratio of -0.09 and a beta of -0.13.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($5.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.16) by $0.24. Equities analysts predict that Revelation Biosciences will post -24.53 EPS for the current year.
Revelation Biosciences Company Profile
Revelation Biosciences is a clinical-stage biotechnology company developing treatments that target the innate immune system. Its research focuses on potential therapies for infectious and other diseases. The company’s lead program, Gemini, is an intranasal formulation of an immune-stimulating compound designed to activate Toll-like receptor 4. Revelation has investigated Gemini as a potential way to help prevent or treat respiratory infections. Revelation’s work is centered on developing its therapeutic candidates; the company has not established a broad commercial product portfolio.
Recommended Stories
- Five stocks we like better than Revelation Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
